Search: onr:"swepub:oai:gup.ub.gu.se/162107" >
Differential effica...
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
-
Aebi, S (author)
-
Sun, Z (author)
-
Braun, D (author)
-
show more...
-
Price, KN (author)
-
Castiglione-Gertsch, M (author)
-
Rabaglio, M (author)
-
Gelber, RD (author)
-
Crivellari, D (author)
-
Lindtner, J (author)
-
Snyder, R (author)
-
- Karlsson, Per, 1963 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
-
Simoncini, E (author)
-
Gusterson, BA (author)
-
Viale, G (author)
-
Regan, MM (author)
-
Coates, AS (author)
-
Goldhirsch, A (author)
-
show less...
-
(creator_code:org_t)
- 2011
- 2011
- English.
-
In: ANNALS OF ONCOLOGY. - 0923-7534. ; 22:9, s. 1981-1987
- Related links:
-
https://gup.ub.gu.se...
Abstract
Subject headings
Close
- Abstract: Background: The benefit of adjuvant chemotherapy in postmenopausal patients with estrogen receptor (ER)positive lymph node-negative breast cancer is being reassessed. Patients and methods: After stratification by ER status, 1669 postmenopausal patients with operable lymph nodenegative breast cancer were randomly assigned to three 28-day courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy followed by tamoxifen for 57 months (CMF/tamoxifen) or to tamoxifen alone for 5 years. Results: ERs were positive in 81% of tumors. At a median follow-up of 13.1 years, patients with ER-positive breast cancers did not benefit from CMF [13-year disease-free survival (DFS) 64% CMF/tamoxifen, 66% tamoxifen; P = 0.99], whereas CMF substantially improved the prognosis of patients with ER-negative breast cancer (13-year DFS 73% versus 57%, P = 0.001). Similarly, breast cancer-free interval (BCFI) was identical in the ER-positive cohort but significantly improved by chemotherapy in the ER-negative cohort (13-year BCFI 80% versus 63%, P = 0.001). CMF had no influence on second nonbreast malignancies or deaths from other causes. Conclusion: CMF is not beneficial in postmenopausal patients with node-negative ER-positive breast cancer but is highly effective within the ER-negative cohort. In the future, other markers of chemotherapy response may define a subset of patients with ER-positive tumors who may benefit from adjuvant chemotherapy.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- adjuvant chemotherapy
- breast cancer
- estrogen receptor
- postmenopause
- tamoxifen
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Aebi, S
-
Sun, Z
-
Braun, D
-
Price, KN
-
Castiglione-Gert ...
-
Rabaglio, M
-
show more...
-
Gelber, RD
-
Crivellari, D
-
Lindtner, J
-
Snyder, R
-
Karlsson, Per, 1 ...
-
Simoncini, E
-
Gusterson, BA
-
Viale, G
-
Regan, MM
-
Coates, AS
-
Goldhirsch, A
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
ANNALS OF ONCOLO ...
- By the university
-
University of Gothenburg